logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
丁

丁瑜 (Yu Ding)

Nanjing Medical University教授
H指数:16
被引数:1,832

个人简介

"A comprehensive expression profile of micrornas in rat's pituitary."

教育背景

  • 2005.01 – 2008.12

    吉林大学 博士 动物遗传育种与繁殖

  • 2002.01 – 2005.12

    吉林农业大学 硕士 动物遗传育种

  • 1998.01 – 2002.12

    吉林农业大学 学士 动物科学专业

工作经历

  • 2024.01 – 至今

    吉林大学动物科学学院

    教授

  • 2016.10 – 2017.10

    University of South Carolina（美国）

    访问学者

  • 2014.01 – 2024.12

    吉林大学动物科学学院

    副教授

  • 2008.01 – 2014.12

    吉林大学动物科学学院

    讲师

  • 2007.12 – 2008.12

    Vanderbilt University（美国）

    联合培养博士

荣誉奖项

  1. 吉林大学优秀博士后（2012）｜吉林大学
  2. 吉林大学课堂教学质量奖（2018）｜吉林大学
  3. 指导硕士研究生获得吉林大学优秀硕士论文（2019）｜吉林大学
  4. 吉林省科技进步二等奖，优质肉牛良种扩繁与生产技术体系得建立与应用（2019）｜吉林省
  5. 第四届全国大学生生命科学创新创业大赛指导教师三等奖（2019）
  6. 第五届全国大学生生命科学创新创业大赛指导教师一等奖（2020）
  7. 吉林省科技进步二等奖，吉林省实验动物质量检测平台建设与检测技术研究（2021）｜吉林省
  8. 吉林大学课堂教学质量奖（2023）｜吉林大学
  9. 指导硕士研究生获得吉林大学优秀硕士论文（2024）｜吉林大学
TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial

TQB3617，一种溴域和末端外抑制剂，在复发或难治性淋巴瘤患者中的研究：一项多中心、I期临床试验

Med
IF11.8
2025-10-270
PRE
Yuchen Zhang; Qingsong Yin; Baitian Zhao; Fang Liu; Su Li; Jun Cai; Xiaojie Fang; Bing Bai; Man Nie; Qihua Zou; Dawei Ding; Xin Wang; Jiajia Zhu; Ding Yu; Xunqiang Wang; Xiquan Zhang; Liang Wang; Yi Xia; Qingqing Cai
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Schmid, Peter; Cortes, Javier; Dent, Rebecca; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Foukakis, Theodoros; Mouret-Reynier, Marie-Ange; Ferreira, Marta; Im, Seock-Ah; Cardoso, Fatima; Ding, Yu; Pan, Wilbur; Tryfonidis, Konstantinos; O'Shaughnessy, Joyce
Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/ HER2-breast cancer: KEYNOTE-756
CANCER RESEARCH
IF16.6
2024-05-026
PRE
Cardoso, Fatima; O'Shaughnessy, Joyce; McArthur, Heather; Schmid, Peter; Cortes, Javier; Harbeck, Nadia; Telli, Melinda; Cescon, David; Fasching, Peter A.; Shao, Zhimin; Loirat, Delphine; Park, Yeon Hee; Fernandez, Manuel Gonzalez; Rubovszky, Gabor; Im, Seock-Ah; Hui, Rina; Takano, Toshimi; Andre, Fabrice; Yasojima, Hiroyuki; Liu, Zhenzhen; Ding, Yu; Jia, Liyi; Karantza, Vassiliki; Tryfonidis, Konstantinos; Bardia, Aditya
KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer
ANNALS OF ONCOLOGY
IF65.4
2023-10-0153
PRE
Cardoso, F.; McArthur, H. L.; Schmid, P.; Cortes, J.; Harbeck, N.; Telli, M. L.; Cescon, D. W.; O'Shaughnessy, J.; Fasching, P.; Shao, Z.; Loirat, D.; Park, Y. H.; Fernandez, M. E. Gonzalez; Liu, Z.; Yasojima, H.; Ding, Y.; Jia, L.; Karantza, V. V.; Tryfonidis, K. E.; Bardia, A.
Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study
CANCER RESEARCH
IF16.6
2023-03-013
PRE
McArthur, Heather; Cortes, Javier; Dent, Rebecca; O'Shaughnessy, Joyce; Pusztai, Lajos; Kuemmel, Sherko; Foukakis, Theodoros; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Untch, Michael; Fasching, Peter A.; Cardoso, Fatima; Denkert, Carsten; Zhu, Yalin; Ding, Yu; Pan, Wilbur; Schmid, Peter
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia

一项为期36周的多中心，随机，双盲，安慰剂对照，平行组，三期临床试验，低聚糖钠治疗轻度至中度阿尔茨海默氏痴呆症

ALZHEIMERS RESEARCH & THERAPY
IF7.6
2021-03-17162
OAAI
Xiao, Shifu; Chan, Piu; Wang, Tao; Hong, Zhen; Wang, Shuzhen; Kuang, Weihong; He, Jincai; Pan, Xiaoping; Zhou, Yuying; Ji, Yong; Wang, Luning; Cheng, Yan; Peng, Ying; Ye, Qinyong; Wang, Xiaoping; Wu, Yuncheng; Qu, Qiumin; Chen, Shengdi; Li, Shuhua; Chen, Wei; Xu, Jun; Peng, Dantao; Zhao, Zhongxin; Li, Yansheng; Zhang, Junjian; Du, Yifeng; Chen, Weixian; Fan, Dongsheng; Yan, Yong; Liu, Xiaowei; Zhang, Wei; Luo, Benyan; Wu, Wenyuan; Shen, Lu; Liu, Chunfeng; Mao, Peixian; Wang, Qiumei; Zhao, Qianhua; Guo, Qihao; Zhou, Yongtao; Li, Yi; Jiang, Lijun; Ren, Wenwei; Ouyang, Yingjun; Wang, Yan; Liu, Shuai; Jia, Jianjun; Zhang, Nan; Liu, Zhonglin; He, Raoli; Feng, Tingyi; Lu, Wenhui; Tang, Huidong; Gao, Ping; Zhang, Yingchun; Chen, Lanlan; Wang, Lei; Yin, You; Xu, Qun; Xiao, Jinsong; Cong, Lin; Cheng, Xi; Zhang, Hui; Gao, Dan; Xia, Minghua; Lian, Tenghong; Peng, Guoping; Zhang, Xu; Jiao, Bin; Hu, Hua; Chen, Xueyan; Guan, Yihui; Cui, Ruixue; Huang, Qiu; Xin, Xianliang; Chen, Hongjian; Ding, Yu; Zhang, Jing; Feng, Teng; Cantillon, Marc; Chen, Kewei; Cummings, Jeffrey L.; Ding, Jian; Geng, Meiyu; Zhang, Zhenxin
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Pembrolizumab单药治疗未经治疗的PD-L1-positive转移性三阴性乳腺癌: II期KEYNOTE-086研究的队列B

ANNALS OF ONCOLOGY
IF65.4
2019-03-012.7K
OAAI
Adams, S.; Loi, S.; Toppmeyer, D.; Cescon, D. W.; De Laurentiis, M.; Nanda, R.; Winer, E. P.; Mukai, H.; Tamura, K.; Armstrong, A.; Liu, M. C.; Iwata, H.; Ryvo, L.; Wimberger, P.; Rugo, H. S.; Tan, A. R.; Jia, L.; Ding, Y.; Karantza, V.; Schmid, P.

研究方向

实验动物新资源创制人类疾病动物模型制备与分子病因学
J
Javier Cortés
H 指数:113论文数:1,480被引数:6.7万
F
Fátima Cardoso
H 指数:103论文数:824被引数:6.5万
N
Nadia Harbeck
H 指数:131论文数:2,063被引数:8.5万
H
Heather L. McArthur
H 指数:43论文数:310被引数:9,958
R
Rina Hui
H 指数:63论文数:252被引数:4.7万
P
Peter Schmid
H 指数:61论文数:509被引数:2.4万
K
Konstantinos Tryfonidis
H 指数:27论文数:147被引数:5,934
P
Peter A. Fasching
H 指数:121论文数:2,055被引数:7.8万
L
LiuMark
H 指数:114论文数:1,397被引数:6.8万
C
Carsten Denkert
H 指数:116论文数:1,285被引数:6.9万